BioCity portfolio company Maxwellia, the UK’s only dedicated expert medicines switching company, has appointed Jack Grimshaw as Finance Director, with broader accountability for Supply Chain & Logistics, Procurement, IT, Legal & HR. The appointment is a reflection of the company’s expansion over the past 12...
BioCity Nottingham-based purification specialists Reach Separations and French drug discovery contract research organisation (CRO), NovAliX, have entered into a unique alliance to develop supercritical fluid chromatography (SFC) capabilities at the NovAliX facility near Strasbourg. Formed in support of Reach Separations’ strategy to grow its European presence,...
Intelligent OMICS, Arctoris and Medicines Discovery Catapult test in silico pipeline for identifying new molecules for cancer treatment BioCity based Intelligent OMICS, supported by Arctoris and Medicines Discovery Catapult, are applying artificial intelligence to find new disease ‘drivers’ and candidate drugs for lung cancer. This...
CognitOss is designed to treat osteomyelitis, a debilitating inflammatory bone infection FDA’s Breakthrough Device Program helps accelerate patient access to more effective treatments. MediCity Nottingham based Locate Bio, an orthobiologics focused regenerative medicine company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has...
Phasefocus, the Sheffield-based makers of Livecyte, the live cell high-content analysis system, are delighted to announce the opening of a second UK office based in BioCity, Nottingham. In response to a significant uptick in Livecyte sales in 2020 and a very positive outlook beyond, Phasefocus has...
Progressive new start-up, Phenotypeca Ltd, is delighted to announce that they have expanded their Board of Directors with Simon Chalk being appointed as a Non-Executive Director at the end of December. Simon will play a significant role in defining Phenotypeca’s business growth strategy. Simon joins Phenotypeca...
Intelligent OMICS, Arctoris and Medicines Discovery Catapult test in silico pipeline for identifying new molecules for cancer treatment BioCity client company, Intelligent OMICS, supported by Arctoris and Medicines Discovery Catapult, are applying artificial intelligence to find new disease ‘drivers’ and candidate drugs for lung cancer....
BioCity investee, Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, today announced the appointment of Dr. Terri Gaskell as its Chief Technology Officer (CTO) and member of the executive team. Dr. Gaskell brings over 20 years of life sciences R&D experience...
Technology that will alert users to the need to replace their face mask has been unveiled by smart packaging company, Insignia Technologies, based at BioCity, Glasgow. Designed to encourage safer mask practice while bringing peace of mind to the public, Insignia’s smart label changes colour to...
Sygnature invests in new capabilities at two of its laboratories. • Automated sample storage for multi-customer, multi-year storage HTS relationships • Flow cytometry at Alderley Park to support ex vivo and in vivo tumour analysis BioCity based Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical...